With the launch of GBM AGILE, a new path has been uncovered—one that accelerates this pace of discovery from bench to bedside, and offers the greatest hope in the fight against cancer. Many important milestones have already been achieved, but there’s so much more on the horizon. Take a look and see how the generous support of our donors is making a difference, one dollar at a time.
As one of the first to support GBM AGILE, we recognized the immediate impact it would have on cancer treatment and care for patients around the world.”Sujuan Ba, PhD, NFCR President & CEO
Milestones We’ve Achieved Together
35+ Trial Sites in the United States
>500 Patients Screened
30+ Global Sites Selected
3 Pharmaceutical Partners
In addition to the progress already achieved, the AGILE trial design will make an even greater impact. The AGILE trial approach will be used to combat other rare and deadly diseases, in the near future.